文献速递肿瘤 PET/CT

18F-FMISO动态PET监测头颈癌放化疗早期反应

Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-05-24

研究纳入72例头颈癌患者,在基线和治疗早期(已接受1周期化疗和5–10次2 Gy放疗)行18F-FMISO动态PET,用不可逆一血浆两组织室模型计算缺氧替代标志物k3和TBR、灌注K1及分布容积DV。结果显示TBR、k3和DV在早期反应扫描中下降,K1无显著变化;k3与TBR相关性从基线明显下降;视觉分析与药代动力学建模在<20%病例中会影响患者管理。

要点

  • TBR、k3和DV在早期反应扫描中下降,K1无显著变化。
  • k3与TBR相关性从基线(r=0.72和0.76)降至早期反应扫描(r=0.39和0.40)。
  • 视觉分析与药代动力学建模结果不一致,在<20%病例中会影响患者管理。

核心结论

  • FMISO动态PET药代动力学建模比单次静态图像能更详细地表征肿瘤微环境和评估头颈癌放化疗反应。
  • 在缺氧缺失会导致治疗降级的临床试验中,视觉分析与药代动力学建模结果的不一致在<20%病例中会影响患者管理。
  • 简单静态PET易于在临床试验中实施,但药代动力学建模的临床适用性仍有待研究。

研究设计与样本

  • 72例头颈癌患者,在定制固定面具下于基线和治疗早期(已接受1周期化疗和5–10次2 Gy分次放疗)行FMISO动态PET扫描(0–30分钟动态采集,随后在注射后约95分钟和约160分钟开始各10分钟静态采集)。
  • 采用不可逆一血浆两组织室模型进行体素级药代动力学建模,计算肿瘤缺氧替代标志物(k3和肿瘤-血比值TBR)、灌注(K1)和FMISO分布容积(DV)。
  • 由经验丰富的核医学医师通过视觉检查得出肿瘤-肌肉比值(TMR),TMR>1.2定义为缺氧。

主要发现

  • 共分析135个病灶。
  • 早期反应扫描中TBR、k3和DV下降,K1无显著变化。
  • k3与TBR相关性从基线扫描(肿瘤内均值和汇总体素值的Pearson r分别为0.72和0.76)明显降至早期反应扫描(Pearson r分别为0.39和0.40)。
  • 发现肿瘤内k3和TBR变化一致与不一致的例子;后者部分由DV变化介导。
  • 13例视觉分析为正常氧合的患者(所有病灶TMR=1.2)中,识别出k3提示存在缺氧的亚体积。

关键数值与推荐

  • TMR>1.2定义为缺氧。
  • 13例视觉分析为正常氧合的患者所有病灶TMR=1.2。
  • 视觉分析与药代动力学建模结果不一致在<20%病例中会影响患者管理。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出简单静态PET易于在临床试验中实施,但药代动力学建模的临床适用性仍有待研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is growing recognition that biologic features of the tumor microenvironment affect the response to cancer therapies and the outcome of cancer patients. In head and neck cancer (HNC) one such feature is hypoxia. We investigated the utility of 18F-fluoromisonidazole (FMISO) dynamic positron emission tomography (dPET) for monitoring the early microenvironmental response to chemoradiotherapy in HNC. EXPERIMENTAL DESIGN: Seventy-two HNC patients underwent FMISO dPET scans in a customized immobilization mask (0-30 min dynamic acquisition, followed by 10 min static acquisitions starting at ∼95 min and ∼160 min post-injection) at baseline and early into treatment where patients have already received one cycle of chemotherapy and anywhere from five to ten fractions of 2 Gy per fraction radiation therapy. Voxelwise pharmacokinetic modeling was conducted using an irreversible one-plasma two-tissue compartment model to calculate surrogate biomarkers of tumor hypoxia (k 3 and Tumor-to-Blood Ratio (TBR)), perfusion (K 1 ) and FMISO distribution volume (DV). Additionally, Tumor-to-Muscle Ratios (TMR) were derived by visual inspection by an experienced nuclear medicine physician, with TMR > 1.2 defining hypoxia. RESULTS: One hundred and thirty-five lesions in total were analyzed. TBR, k 3 and DV decreased on early response scans, while no significant change was observed for K 1 . The k 3 -TBR correlation decreased substantially from baseline scans (Pearson's r = 0.72 and 0.76 for mean intratumor and pooled voxelwise values, respectively) to early response scans (Pearson's r = 0.39 and 0.40, respectively). Both concordant and discordant examples of changes in intratumor k 3 and TBR were identified; the latter partially mediated by the change in DV. In 13 normoxic patients according to visual analysis (all having lesions with TMR = 1.2), subvolumes were identified where k 3 indicated the presence of hypoxia. CONCLUSION: Pharmacokinetic modeling of FMISO dynamic PET reveals a more detailed characterization of the tumor microenvironment and assessment of response to chemoradiotherapy in HNC patients than a single static image does. In a clinical trial where absence of hypoxia in primary tumor and lymph nodes would lead to de-escalation of therapy, the observed disagreement between visual analysis and pharmacokinetic modeling results would have affected patient management in <20% cases. While simple static PET imaging is easily implemented for clinical trials, the clinical applicability of pharmacokinetic modeling remains to be investigated.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Grkovski M, Lee NY, Schöder H, et al. Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer. Eur J Nucl Med Mol Imaging. 2017. PMID: 28540417. doi:10.1007/s00259-017-3720-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。